Article

Evaluation of MARC1 Variants and Extracellular Vesicle Cytokeratin-18 as Predictive Biomarkers in a group of Egyptian MASLD and MASH patients

2026-02-18

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive inflammatory phenotype, metabolic dysfunction-associated steatohepatitis (MASH), represent an increasing global health challenge. Disease progression reflects a complex interaction between metabolic stress and genetic susceptibility. Variants in the mitochondrial amidoxime re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7906602f-9cca-5e14-a07c-2f11c1338c2f
DOI: 10.21203/rs.3.rs-8796724/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluation of MARC1 Variants and Extracellular Vesicle Cytokeratin-18 as Predictive Biomarkers in a group of Egyptian MASLD and MASH patientsDOI 10.21203/rs.3.rs-8796724/v1Read

A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitisSemantic proximity Read

GCKR genetic variants and circulating FGF21 define a metabolic risk signature in Metabolic-associated Steatotic Liver diseaseSemantic proximity Read

The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologiesSemantic proximity Read

Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation.Semantic proximity Read

Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology.Semantic proximity Read

Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.Semantic proximity Read

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsSemantic proximity Read

Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver diseaseSemantic proximity Read

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtypingSemantic proximity Read

Novel genetic insights into the roles of amino acids in metabolic dysfunction-associated steatotic liver diseaseSemantic proximity Read

Genetic Predisposition to MASLD: Potential for Therapeutic Management.Semantic proximity Read

Extracellular Vesicles as Biomarkers for Steatosis Stages in MASLD Patients: an Algorithmic Approach Using Explainable Artificial IntelligenceSemantic proximity Read